Marinomed Biotech AG

BRIEF

published on 03/23/2026 at 17:49, 2 days 17 hours ago

Marinomed Biotech AG: Capital Increase and 2025 Financial Outlook

Capital Increase Marinomed 2025 Results Liquidity Gap Shareholder Opportunity
PRESS RELEASE

published on 03/23/2026 at 17:44, 2 days 17 hours ago

Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research issues a Buy recommendation with a target price of EUR 50 for Marinomed Biotech AG due to a capital increase and delayed Carragelose earn-out revenues

First Berlin Equity Research Buy Recommendation Capital Increase Marinomed Biotech AG Carragelose Earn-out
BRIEF

published on 03/19/2026 at 16:52, 6 days 18 hours ago

Marinomed Biotech Initiates Capital Increase with Subscription Rights

Capital Increase Subscription Rights Marinomed Biotech Fiscal Outlook Liquidity Gap
PRESS RELEASE

published on 03/19/2026 at 16:47, 6 days 18 hours ago

Marinomed Biotech Announces Capital increase with subscription rights
Marinomed Biotech plans a capital increase with subscription rights supported by an institutional investor to meet short-term capital needs. Preliminary financial figures for 2025 show revenue growth

Capital Increase Financial Figures Subscription Rights Marinomed Biotech Institutional Investor
BRIEF

published on 03/19/2026 at 16:19, 6 days 19 hours ago

Marinomed Biotech AG Initiates Cash Capital Increase

Capital Increase Subscription Rights Marinomed Biotech Carragelose Transfer Short-term Liquidity
PRESS RELEASE

published on 03/19/2026 at 16:14, 6 days 19 hours ago

EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
Marinomed Biotech AG announces cash capital increase of EUR 2 million to cover short-term capital needs. Existing shareholders will have subscription rights. Goal is to generate at least EUR 2 million in gross proceeds

Cash Capital Increase Marinomed Biotech AG Subscription Rights EUR 2 Million Short-term Capital Requirements
BRIEF

published on 10/06/2025 at 15:01, 5 months 19 days ago

Marinomed Biotech AG Explores Strategic Alternatives for Marinosolv Platform

Strategic Options Marinomed Biotech Biotech Innovation Marinosolv Platform Health Partnerships
PRESS RELEASE

published on 10/06/2025 at 14:56, 5 months 19 days ago

EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Marinomed Biotech AG initiates strategic review of Marinosolv platform following successful capital measures. Evaluation may include partnerships for Budesolv and Tacrosolv projects

Strategic Partnerships Marinomed Biotech AG Strategic Review Marinosolv Platform Capital Measures
BRIEF

published on 10/01/2025 at 12:23, 5 months 24 days ago

Marinomed Biotech AG: First Berlin Equity Reiterates Buy Rating

Financial Results Buy Recommendation Capital Increase Marinomed Biotech AG Licensing Deals
PRESS RELEASE

published on 10/01/2025 at 12:18, 5 months 24 days ago

Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirmed a Buy rating and EUR 50.00 price target for Marinomed Biotech AG. H1 results were in line with expectations, with nearly tripled sales and positive AEBITDA amid strategic financial moves

First Berlin Equity Research BUY Rating Marinomed Biotech AG H1 Results EUR 50.00 Price Target

Published on 03/26/2026 at 11:07, 26 minutes ago

U.S. Mined and Refined Metals as well as Rare Earth Elements to Be Tokenized in Historic American Strategic Minerals and Datavault AI Deal
Published on 03/26/2026 at 11:00, 33 minutes ago

Pivotree Announces Fourth Quarter 2025 Results
Published on 03/26/2026 at 11:00, 33 minutes ago

Stagwell Expands the Harris Poll's Harrisquest Across Europe
Published on 03/26/2026 at 08:05, 3 hours 28 minutes ago

Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 6 hours 38 minutes ago

Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives

View all ACCESSWIRE

Published on 03/26/2026 at 11:03, 30 minutes ago

EQS-Adhoc: VIDINEXT AG: Marketing agreement with Telekom Deutschland GmbH
Published on 03/26/2026 at 11:00, 33 minutes ago

Genel Energy PLC: Posting of Annual Report and Notice of AGM
Published on 03/26/2026 at 11:00, 33 minutes ago

Genel Energy PLC: Report on payments to governments for the year 2025
Published on 03/26/2026 at 11:00, 33 minutes ago

ABB Ltd: ABB share buybacks - March 19, 2026 - March 25, 2026
Published on 03/26/2026 at 11:00, 33 minutes ago

Independent study reveals 44% ROI with EQS Compliance Cockpit and payback in under six months

View all EQS

Published on 03/26/2026 at 08:57, 2 hours 35 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 4 hours 3 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 16 hours 40 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 17 hours 2 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 17 hours 48 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE

News